TScan Therapeutics, Inc. (TCRX) Misses Q4 EPS by 6c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q4 EPS of ($0.78), $0.06 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $4.1 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c